OptiNose Files Proxy Statement
| Field | Detail |
|---|---|
| Company | Optinose, Inc. |
| Form Type | DEFA14A |
| Filed Date | Mar 21, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, sec-filing, governance
TL;DR
OptiNose filed its proxy statement on 3/21/25, no fee required.
AI Summary
OptiNose, Inc. filed a DEFA14A on March 21, 2025, related to communications made in connection with its upcoming proxy statement. The filing indicates no fee was required for this submission, which is a definitive proxy statement.
Why It Matters
This filing is a routine but important step in corporate governance, informing shareholders about matters to be voted on at the company's annual meeting.
Risk Assessment
Risk Level: low — This is a standard regulatory filing (DEFA14A) for a public company, not indicating any unusual financial or operational risks.
Key Players & Entities
- OptiNose, Inc. (company) — Registrant
- 20250321 (date) — Filing Date
- DEFA14A (document_type) — Filing Type
FAQ
What is the purpose of a DEFA14A filing?
A DEFA14A filing, also known as a Schedule 14A, is a proxy statement filed with the SEC by a company to solicit proxies from its shareholders for an upcoming meeting.
When was this specific DEFA14A filed by OptiNose, Inc.?
OptiNose, Inc. filed this DEFA14A on March 21, 2025.
Was a fee required for this filing?
No, the filing explicitly states 'No fee required.'
What is the SIC code for OptiNose, Inc.?
The Standard Industrial Classification (SIC) code for OptiNose, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Where is OptiNose, Inc. headquartered?
OptiNose, Inc. is located in Yardley, Pennsylvania, with its business and mailing address at 777 Township Line Road, Suite 300, Yardley, PA 19067.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on March 21, 2025 regarding OptiNose, Inc..